Outcome of different risk groups of patients with aggressive lymphomas according to the IPI15 in the rituximab era17
| Risk group . | Number of risk factors* . | 3-year EFS (%) . | 3-year PFS (%) . | 3-year OS (%) . |
|---|---|---|---|---|
| Low | 0.1 | 81 | 87 | 91 |
| Low-intermediate | 2 | 68.5 | 74.7 | 81 |
| High-intermediate | 3 | 53 | 59 | 65 |
| High | 4.5 | 50 | 56 | 59 |
| Risk group . | Number of risk factors* . | 3-year EFS (%) . | 3-year PFS (%) . | 3-year OS (%) . |
|---|---|---|---|---|
| Low | 0.1 | 81 | 87 | 91 |
| Low-intermediate | 2 | 68.5 | 74.7 | 81 |
| High-intermediate | 3 | 53 | 59 | 65 |
| High | 4.5 | 50 | 56 | 59 |
The following parameters have been shown to have a negative impact on outcome: age > 60 years, elevated serum lactate dehydrogenase, advanced stage (III and IV according to Ann Arbor), poor performance status (ECOG > 1), and > 1 extranodal site of involvement.